Manuscripts

Miao D, Yu L, Tiberti C, Cuthbertson DD, Rewers MJ, DiMario U, Eisenbarth GS, Dotta F. ICA512(IA-2) Epitope Specific Assays Distinguish Transient from Diabetes Associated Autoantibodies. J Autoimmun 2002; 18:191-6. [Abstract] [$Full Text$]

Diamond B, Bluestone J, Wofsy D. The immune tolerance network and rheumatic disease: immune tolerance comes to the clinic. Arthritis Rheum 44:1730-5, 2001. [PubMed] [$Reprint$]

Bluestone JA, Matthews JB. The immune tolerance network--an NIH/JDF-supported initiative to bring tolerance research into the clinic: a major new resource for clinical immunologists. Clin Immunol 96:171-3, 2000. [Abstract] [$Reprint$]


Conference Abstracts/Presentations

Herold K, Gitelman S, Masharani U, Greenbaum C, Hagopian W, Gottlieb P, Muir A, Ramos E, Tomlin N, Bluestone JA. Treatment with hOKT3γ1(Ala-Ala) improves insulin responses and reduces insulin requirements in patients with new onset Type 1 diabetes (T1DM). [Abstract 1885] XXIIth International Congress of Immunology, Montreal, QC, Canada, July 18-23, 2004. [Abstract]

Brooks-Worrell BM, Dosch HM, Herold K, Seyfert V, Greenbaum CJ, Gitelman SE, Palmer JP. Marked Differences in T Cell Reactivity in Recently Diagnosed Type 1 Diabetes Patients Versus Controls. [Abstract 2778] XXIIth International Congress of Immunology, Montreal, QC, Canada, July 18-23, 2004. [Abstract]

Herold K, Gitelman S, Masharani U, Greenbaum C, Hagopian W, Gottlieb P, Muir A, Ramos E, Tomilin N, Bluestone JA. Treatment with hOKT3γ1(Ala-Ala) improves insulin responses and reduces insulin requirements in patients with new onset Type 1 diabetes (T1DM). [Abstract 271-OR] 64th Scientific Sessions of the American Diabetes Association, Orlando, FL, June 4-8, 2004. [Abstract]

Khoury SJ, Bourcier K, Buckle G, Bikowski M, Guttmann C, Rioux P, Jauregui K. Phase I trial of CTLA4Ig treatment in MS. [Abstract S12.003] 56th Meeting of the American Academy of Neurology, San Francisco, CA, April 24 - May 1, 2004. [Abstract]